Mergers & Acquisitions 2022 Annual Review

30 MORRISON FOERSTER MYCHEM Morrison Foerster advised MyChem, a privately held provider of proprie nucleotides to customers in the diagnostics, pharma, genomics, and res in connection with its sale to Maravai, a provider of critical products to e development of drug therapies, diagnostics, and novel vaccines and to on human diseases. This acquisition will expand Maravai’s product offering of strategic input growing markets for therapeutics and vaccine applications and will furth Maravai’s innovation capabilities with additional R&D resources.